Audrey D. Zhang
@audreydzhang.bsky.social
Primary care physician and health services researcher. General medicine fellow at Harvard/BIDMC. Studying how to improve quality of care for older adults. https://linktr.ee/audreydzhang
Many more pieces like this could be written to show the impact of sustained federal investment in US biomedical research. This one has a great table highlighting the role of NIH funding in some of our greatest gains against chronic disease in the past 80 years. www.ahajournals.org/doi/full/10....
February 20, 2025 at 5:24 PM
Many more pieces like this could be written to show the impact of sustained federal investment in US biomedical research. This one has a great table highlighting the role of NIH funding in some of our greatest gains against chronic disease in the past 80 years. www.ahajournals.org/doi/full/10....
I've caught myself thinking some version of this meme now when I hear folks describing their studies as target trial emulations.
January 24, 2025 at 11:08 PM
I've caught myself thinking some version of this meme now when I hear folks describing their studies as target trial emulations.
#NewLitHighlights #HealthPolicy
Nurse practitioners and physician assistants are now responsible for over a quarter of outpatient visits in traditional Medicare - still a lot of room to understand how to optimize their role in clinical care: www.bmj.com/content/382/...
Nurse practitioners and physician assistants are now responsible for over a quarter of outpatient visits in traditional Medicare - still a lot of room to understand how to optimize their role in clinical care: www.bmj.com/content/382/...
October 27, 2023 at 1:30 AM
#NewLitHighlights #HealthPolicy
Nurse practitioners and physician assistants are now responsible for over a quarter of outpatient visits in traditional Medicare - still a lot of room to understand how to optimize their role in clinical care: www.bmj.com/content/382/...
Nurse practitioners and physician assistants are now responsible for over a quarter of outpatient visits in traditional Medicare - still a lot of room to understand how to optimize their role in clinical care: www.bmj.com/content/382/...
The most common type of payment for both physicians and APCs was for food/beverage.
Overall, APCs were more likely to receive payments for food/beverage and physicians more likely to receive payments of every other type (e.g. consulting, commercial interests).
Overall, APCs were more likely to receive payments for food/beverage and physicians more likely to receive payments of every other type (e.g. consulting, commercial interests).
January 24, 2025 at 11:03 PM
The most common type of payment for both physicians and APCs was for food/beverage.
Overall, APCs were more likely to receive payments for food/beverage and physicians more likely to receive payments of every other type (e.g. consulting, commercial interests).
Overall, APCs were more likely to receive payments for food/beverage and physicians more likely to receive payments of every other type (e.g. consulting, commercial interests).
The median payment was $175 among physicians and $118 among APCs, with a greater range of payment values seen among physicians.
January 24, 2025 at 10:58 PM
The median payment was $175 among physicians and $118 among APCs, with a greater range of payment values seen among physicians.
We used 2021 #NPPES and #OpenPayments data to identify payments to NPs, PAs, CRNAs, certified nurse-midwives, clinical nurse specialists, and anesthesiologist assistants in addition to physicians.
Over a third of both physicians and APCs received non-research industry payments.
Over a third of both physicians and APCs received non-research industry payments.
January 24, 2025 at 10:53 PM
We used 2021 #NPPES and #OpenPayments data to identify payments to NPs, PAs, CRNAs, certified nurse-midwives, clinical nurse specialists, and anesthesiologist assistants in addition to physicians.
Over a third of both physicians and APCs received non-research industry payments.
Over a third of both physicians and APCs received non-research industry payments.
"Recommendations for outcome measurement for deprescribing intervention studies" (@DeprescribeUS Measures Working Grp) - lack of standardization in deprescribing measures poses challenges to interpretation, with many opportunities for further development:...
January 24, 2025 at 10:48 PM
"Recommendations for outcome measurement for deprescribing intervention studies" (@DeprescribeUS Measures Working Grp) - lack of standardization in deprescribing measures poses challenges to interpretation, with many opportunities for further development:...
“Moving Deprescribing Upstream” (@michelleskeller @SarahVordenberg @MikeSteinman) - or as I've started to think of it, "the process of deprescribing begins with prescribing": https://link.springer.com/article/10.1007/s11606-022-07537-x
January 24, 2025 at 10:48 PM
“Moving Deprescribing Upstream” (@michelleskeller @SarahVordenberg @MikeSteinman) - or as I've started to think of it, "the process of deprescribing begins with prescribing": https://link.springer.com/article/10.1007/s11606-022-07537-x
Pair with this new study led by @jeromie_b with a different approach to estimating @CMSGov spending on “dangling” accelerated approval drugs/indications without full approval (~$1-2B in 2019): https://www.acpjournals.org/doi/10.7326/M21-4442
January 24, 2025 at 10:48 PM
Pair with this new study led by @jeromie_b with a different approach to estimating @CMSGov spending on “dangling” accelerated approval drugs/indications without full approval (~$1-2B in 2019): https://www.acpjournals.org/doi/10.7326/M21-4442
Catching up on new paper from @SkydelJ on @CMSGov spending on drugs approved by @US_FDA Accelerated Approval pathway - huge sum ($60+B/9y) involved, most for drugs with unconfirmed benefit or “confirmed” with surrogate endpoints only:...
January 24, 2025 at 10:48 PM
Catching up on new paper from @SkydelJ on @CMSGov spending on drugs approved by @US_FDA Accelerated Approval pathway - huge sum ($60+B/9y) involved, most for drugs with unconfirmed benefit or “confirmed” with surrogate endpoints only:...
Great to see lots of interest in the recent aducanumab saga at policy update with @Aging_MD at #AGS22.
For those still here, I’ll be presenting at Sat 5/13 HSR Paper Session on representativeness of trial participants along the pipeline of anti-amyloid mAbs for AD:
For those still here, I’ll be presenting at Sat 5/13 HSR Paper Session on representativeness of trial participants along the pipeline of anti-amyloid mAbs for AD:
January 24, 2025 at 10:48 PM
Great to see lots of interest in the recent aducanumab saga at policy update with @Aging_MD at #AGS22.
For those still here, I’ll be presenting at Sat 5/13 HSR Paper Session on representativeness of trial participants along the pipeline of anti-amyloid mAbs for AD:
For those still here, I’ll be presenting at Sat 5/13 HSR Paper Session on representativeness of trial participants along the pipeline of anti-amyloid mAbs for AD:
Have been thinking a lot recently about this point highlighted by @VouriPharmD - #deprescribing is often framed as a geriatric issue but the framework is applicable in many settings beyond: #AGS22
January 24, 2025 at 10:48 PM
Have been thinking a lot recently about this point highlighted by @VouriPharmD - #deprescribing is often framed as a geriatric issue but the framework is applicable in many settings beyond: #AGS22
Obesity care is primary care - appreciate focus on interventions beyond behavioral ones. We have options!
And important to remember potential role of obesogenic medications - new study showing high prevalence among people who are overweight/obese:...
And important to remember potential role of obesogenic medications - new study showing high prevalence among people who are overweight/obese:...
January 24, 2025 at 10:48 PM
Obesity care is primary care - appreciate focus on interventions beyond behavioral ones. We have options!
And important to remember potential role of obesogenic medications - new study showing high prevalence among people who are overweight/obese:...
And important to remember potential role of obesogenic medications - new study showing high prevalence among people who are overweight/obese:...
Great general principle to keep in mind with #BeersCriteria update at #AGS2022 - discontinuation of a drug is not equivalent to avoiding initiation of a drug. Early exploration in subgroup analysis of ASPREE and ripe for further investigation:...
January 24, 2025 at 10:48 PM
Great general principle to keep in mind with #BeersCriteria update at #AGS2022 - discontinuation of a drug is not equivalent to avoiding initiation of a drug. Early exploration in subgroup analysis of ASPREE and ripe for further investigation:...
Proposed #BeersCriteria update on antipsychotics at #AGS2022 spurring a lot of comments/discussion on appropriate conditions for use - recognizing trade-offs and nuances of meeting multiple patient goals including remaining in the community:
January 24, 2025 at 10:53 PM
Proposed #BeersCriteria update on antipsychotics at #AGS2022 spurring a lot of comments/discussion on appropriate conditions for use - recognizing trade-offs and nuances of meeting multiple patient goals including remaining in the community:
Proposed 2022 #BeersCriteria changes presented at #AGS2022 - notably to antiplatelet/anticoagulation recs:
January 24, 2025 at 10:53 PM
Proposed 2022 #BeersCriteria changes presented at #AGS2022 - notably to antiplatelet/anticoagulation recs:
So many opportunities for further research on the process of #deprescribing and measuring value. Inspiring to be surrounded by those who are tackling these questions at @DeprescribeUS #USDeN2022Live:
January 24, 2025 at 10:58 PM
So many opportunities for further research on the process of #deprescribing and measuring value. Inspiring to be surrounded by those who are tackling these questions at @DeprescribeUS #USDeN2022Live:
Inspiring @DeprescribeUS #USDeN2022Live keynote by Dr. Barbara Farrell on developing guidelines for the process of #deprescribing:
January 24, 2025 at 10:53 PM
Inspiring @DeprescribeUS #USDeN2022Live keynote by Dr. Barbara Farrell on developing guidelines for the process of #deprescribing:
Great start to @DeprescribeUS #USDeN2022Live meeting!
@MikeSteinman highlights gap in research on deprescribing in communities of color - an opportunity for further #pharmacoequity research. @UREssien
@MikeSteinman highlights gap in research on deprescribing in communities of color - an opportunity for further #pharmacoequity research. @UREssien
January 24, 2025 at 10:53 PM
Great start to @DeprescribeUS #USDeN2022Live meeting!
@MikeSteinman highlights gap in research on deprescribing in communities of color - an opportunity for further #pharmacoequity research. @UREssien
@MikeSteinman highlights gap in research on deprescribing in communities of color - an opportunity for further #pharmacoequity research. @UREssien
Excited to be heading to #SGIM22 - first in-person conference in 3 years! Thanks to @SocietyGIM for sponsoring me as a Young Scholar in GIM. Looking forward to the next few days with my academic home. #ProudtobeGIM
January 24, 2025 at 10:58 PM
Excited to be heading to #SGIM22 - first in-person conference in 3 years! Thanks to @SocietyGIM for sponsoring me as a Young Scholar in GIM. Looking forward to the next few days with my academic home. #ProudtobeGIM
Does remind me of this by @KristieWeir exploring how apparently "contradicting" attitudes towards deprescribing - like non-overlapping portions of the Venn diagram - could represent different typologies of internally-consistent views towards medicines:...
January 24, 2025 at 11:08 PM
Does remind me of this by @KristieWeir exploring how apparently "contradicting" attitudes towards deprescribing - like non-overlapping portions of the Venn diagram - could represent different typologies of internally-consistent views towards medicines:...
"Attitudes toward deprescribing among older adults with dementia in the United States" (@matthew_growdon, @MikeSteinman) - adds to our understanding of nuanced attitudes towards polypharmacy and deprescribing in people with dementia:...
January 24, 2025 at 10:58 PM
"Attitudes toward deprescribing among older adults with dementia in the United States" (@matthew_growdon, @MikeSteinman) - adds to our understanding of nuanced attitudes towards polypharmacy and deprescribing in people with dementia:...
"Outcome Measures for Interventions to Reduce Inappropriate Chronic Drugs: A Narrative Review" (@aubert_carole @EveKerrMD) - chronic drug deprescribing studies use wide variety of measures; room to standardize and esp. develop clinically-relevant outcomes:...
January 24, 2025 at 10:58 PM
"Outcome Measures for Interventions to Reduce Inappropriate Chronic Drugs: A Narrative Review" (@aubert_carole @EveKerrMD) - chronic drug deprescribing studies use wide variety of measures; room to standardize and esp. develop clinically-relevant outcomes:...
"Evaluating the use of prescription sequence symmetry analysis as a pharmacovigilance tool: A scoping review" (@DrEarlIV, @VouriPharmD) - new-to-me neat self-controlled method of identifying/testing prescribing cascades:...
January 24, 2025 at 10:58 PM
"Evaluating the use of prescription sequence symmetry analysis as a pharmacovigilance tool: A scoping review" (@DrEarlIV, @VouriPharmD) - new-to-me neat self-controlled method of identifying/testing prescribing cascades:...
Late to this - @TheWonkologist @peterbachmd examine 30 years of FDA policy through the lens of PDUFA - which allowed industry to gain negotiating power on FDA policy through the FDA budget:...
January 24, 2025 at 10:58 PM
Late to this - @TheWonkologist @peterbachmd examine 30 years of FDA policy through the lens of PDUFA - which allowed industry to gain negotiating power on FDA policy through the FDA budget:...